Study Comparing Eye Pressure Treatments Simbrinza and Rocklatan Versus Cosopt and Latanoprost in Adults with Mild to Moderate Open-Angle Glaucoma

What this Trial Is About

Researchers are evaluating adults with mild to moderate open-angle glaucoma OAG who have been using a combination of Cosopt and Latanoprost eye medications for at least one month. This phase 4, randomized study compares the effectiveness and tolerability of two treatment combinations Simbrinza and Rocklatan versus Cosopt and Latanoprost. The purpose is to assess how these treatments lower eye pressure in patients with this condition. Participants will be randomly assigned to receive either Simbrinza containing brinzolamide and brimonidine tartrate combined with Rocklatan containing netarsudil and latanoprost or the current standard treatment of Cosopt dorzolamide hydrochloride and timolol maleate combined with Latanoprost. Both treatments are given as eye drops, and the study will monitor changes in eye pressure over an 8-week period. During the study, participants will have their eye pressure measured at different times of the day to observe the effects of the treatments. Researchers will collect data on the decrease in mean diurnal intraocular pressure IOP from the start of the study to week 8. Safety and tolerability will also be monitored throughout the trial. The total duration of participation is approximately 8 weeks, ending with a final assessment of eye pressure reduction.

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost